Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 5/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 7/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26007758 | 0.87 | GRIA2 (0.38) | GRIA2GRIN2API4KAPI4KBPIK3CG | |
| SCHEMBL26006408 | 0.78 | GRIA2 (0.48) | GRIA2GRIN2API4KAPI4KBPIK3CG | |
| SCHEMBL14501877 | 0.78 | ACACB (0.40) | PI4KAPI4KBPIK3CGPIK3CDPIK3CA | |
| SCHEMBL22214031 | 0.76 | PTGS2 (0.38) | MAPT | |
| SCHEMBL21350503 | 0.75 | MAPT (0.48) | MAPTOPRM1OPRK1OPRL1 | |
| SCHEMBL1035189 | 0.75 | PI4KA (0.45) | GRIA2GRIN2API4KAPI4KBPIK3CG | |
| SCHEMBL1039375 | 0.75 | PI4KA (0.45) | GRIA2GRIN2API4KAPI4KBPIK3CG | |
| SCHEMBL22971667 | 0.73 | IDH1 (0.35) | MAPT | |
| SCHEMBL12546246 | 0.73 | MAPT (0.40) | MAPTOPRM1OPRK1OPRL1 | |
| SCHEMBL1346577 | 0.72 | GRIA2 (0.43) | GRIA2GRIN2API4KAPI4KBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, CHEK2 | GRIA2 413/4885GRIN2A 1479/4885PI4KA 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.